The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Issues Warning for Joint Pain from Diabetes Drugs

FDA Issues Warning for Joint Pain from Diabetes Drugs

September 23, 2015 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Drugs_500x270The U.S. Food and Drug Administration (FDA) has issued a new warning and precaution about the risks of severe and disabling joint pain related to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors used to treat diabetes.1 Drugs in this class include alogliptin (Nesina), linagliptin (Tradjenta), saxagliptin (Onglyza) and sitagliptin (Januvia). All single-agent DPP-4 inhibitors and their combinations are subject to the warning. Combinations include sitagliptin/metformin and ER (Janumet/XR), saxagliptin/metformin ER (Kombiglyze XR), linagliptin/empagliflozin (Glyxambi), linaglitptin/metformin (Jentadueto), alogliptin/metformin (Kazano) and alogliptin/pioglitazone (Oseni).

You Might Also Like
  • FDA Warns of Severe Joint Pain Risk with DPP-4 Diabetes Drugs
  • Tofacitinib Promising for Psoriatic Arthritis & FDA Issues Alert for Warning for Saxagliptin & Alogliptin Diabetes Treatments
  • FDA Issues Stronger Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Warning
Also By This Author
  • Tofacitinib Released from FDA REMS Requirement; Plus Biosimilars for Etanercept & Adalimumab Show Promise

The onset of joint pain in patients taking these therapies can occur at any time during treatment, from one day to years after starting the drug therapy. Patients experienced symptom relief after discontinuing the medication. When re-challenged with a DPP-4 inhibitor, some patients had a recurrence of severe joint pain.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Healthcare professionals should consider DPP-4 inhibitors as a possible cause of severe and persistent joint pain in patients receiving these treatments if other causes are ruled out. Healthcare professionals are encouraged to report any suspected adverse drug reactions to the FDA’s MedWatch Program. Directions for the program’s Online Voluntary Reporting Form are available online, as well as more detailed information about the FDA Adverse Event Reporting System (FAERS).2–4

Additionally, the FDA has strengthened the warnings and precautions sections of the drug labels for the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin (Invokana, Invokamet).5 This warning is related to an increased risk of bone fractures. The FDA added new information about decreases in bone mineral density seen with canagliflozin at both the hip and spine areas. Healthcare professionals should consider factors that contribute to fracture risk prior to starting patients on canagliflozin. Bone fractures have been seen in patients taking canagliflozin as early as 12 weeks after beginning treatment.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. U.S. Food and Drug Administration. FDA drug safety communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. 2015 Aug 25.
  2. U.S. Food and Drug Administration. MedWatch online voluntary reporting form. 2015.
  3. U.S. Food and Drug Administration. MedWatch voluntary report. 2015.
  4. U.S. Food and Drug Administration. FDA adverse event reporting system (FAERS). 2015.
  5. U.S. Food and Drug Administration. Invokana and Invokamet (canagliflozin): Drug safety communication—new information on bone fracture risk and decreased bone mineral density. 2015 Sep 10.

Filed Under: Drug Updates, Safety Tagged With: adverse event, diabetes, DPP-4 inhibitor, drug, FDA, Food and Drug Administration, Joint Pain

You Might Also Like:
  • FDA Warns of Severe Joint Pain Risk with DPP-4 Diabetes Drugs
  • Tofacitinib Promising for Psoriatic Arthritis & FDA Issues Alert for Warning for Saxagliptin & Alogliptin Diabetes Treatments
  • FDA Issues Stronger Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Warning
  • FDA Issues Stronger NSAIDs Warning

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.